2024
Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons
Swartwood N, Li Y, Regan M, Marks S, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, McCree D, Myles R, Salomon J, Self J, Menzies N. Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons. JAMA Network Open 2024, 7: e2431988. PMID: 39254977, PMCID: PMC11388029, DOI: 10.1001/jamanetworkopen.2024.31988.Peer-Reviewed Original ResearchConceptsUS-born personsEthnic disparitiesCase-fatality rateTB deathsTB casesTB incidenceSex-adjusted incidenceNational TB surveillance dataTB surveillance dataQuality-adjusted life yearsDistrict of ColumbiaTB disparitiesHealth outcomesEconomic outcomesFuture healthOutcome of TBUS-bornTB outcomesEstimate healthLife yearsSocietal costsTB burdenSocietal perspectiveGeneralized additive regression modelsGoal attainmentCost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealthQuantifying gaps in the tuberculosis care cascade in Brazil: A mathematical model study using national program data
Emani S, Alves K, Alves L, da Silva D, Oliveira P, Castro M, Cohen T, de Macedo Couto R, Sanchez M, Menzies N. Quantifying gaps in the tuberculosis care cascade in Brazil: A mathematical model study using national program data. PLOS Medicine 2024, 21: e1004361. PMID: 38512968, PMCID: PMC10994550, DOI: 10.1371/journal.pmed.1004361.Peer-Reviewed Original ResearchDisability-adjusted life yearsLoss to follow-upTreatment loss to follow-upCare cascadeHealth lossDelay to diagnosisTB diseaseTB diagnosisReduce delays to diagnosisHuman immunodeficiency virusContribution of social factorsTotal health system costsCare cascade outcomesTB care cascadeMortality Information SystemBurden of TB diseaseHealth system costsLifetime health outcomesNotifiable Diseases Information SystemBurden of diseaseIncident TB casesState of residenceNational program dataFollow-upHealth outcomes
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility